THIRD HARMONIC BIO INC (THRD) Stock News
NASDAQ:THRD - Nasdaq - US88427A1079 - Common Stock - Currency: USD
THRD Latest News, Press Relases and Analysis
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives...
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered
The company plans to file a certification of dissolution with the Secretary of the State of Delaware in the third quarter of 2025, provided that stockholders authorize the decision at its annual meeting of stockholders on June 5.
Third Harmonic outlines plans for dissolution
The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it pursued after halting work on a different immune drug in 2022.
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing...
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling...
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing...
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q2 2024
THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the second quarter of 2024.
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing...
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
Third Harmonic Bio to Participate in Upcoming Investor Conferences